Skip to main content
padlock icon - secure page this page is secure

Open Access Micheliolide inhibits gastric cancer growth in vitro and in vivo via blockade of the IL-6/STAT3 pathway

Download Article:
 Download
(PDF 1,448.4 kb)
 
Upregulation of pro-inflammatory cytokine interleukin (IL)-6 is observed in gastric cancer tissue, and high IL-6 serum levels predict a poor prognosis of gastric cancer patients. The IL-6/STAT3 pathway has been confirmed to play essential roles in the process of carcinogenesis, including gastric cancer. Thus, blockade of the IL-6/STAT3 pathway may be a potentially effective therapeutic option for gastric cancer. Micheliolide (MCL), a guaianolide sesquiterpene lactone, possesses anti-inflamma tory properties and can attenuate the IL-6 level. In addition, MCL has been widely reported to possess anti-tumor activity. But the anti-cancer effect of MCL on gastric cancer is unclear. In this study, we detected the effects of MCL on gastric cancer cell proliferation and apoptosis by performing MTT, colony formation, TUNEL and western blot assays, and found that MCL inhibited gastric cancer cell proliferation and promoted apoptosis in vitro. We further investigated the molecular mechanism by which MCL played an efficient role against gastric cancer, and found that the IL-6/STAT3 pathway is involved in the anti-cancer effect of MCL on gastric cancer. In vivo experiments further confirmed this conclusion. Taken together, MCL inhibits gastric cancer growth in vitro and in vivo via blockade of IL-6/STAT3 pathway.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Publication date: March 1, 2019

More about this publication?
  • Pharmazie is a leading journal in the field of pharmaceutical sciences. As a peer-reviewed scientific journal, Pharmazie is regularly indexed in the relevant databases like Web of science, Journal Citation Reports and many others. The journal is open for submissions from the whole spectrum of pharnaceutical sciences including Pharmaceutical Chemistry, Experimental and Clinical Pharmacology, Drug Analysis, Pharmaceutics, Pharmaceutical Biology, Clinical Pharmacy etc.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more